The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesothelioma.
D. C. Christoph
Other Remuneration - Lilly
C. Mascaux
No relevant relationships to disclose
M. W. Wynes
No relevant relationships to disclose
B. Reyna Asuncion
No relevant relationships to disclose
J. Wohlschlaeger
No relevant relationships to disclose
D. Theegarten
Consultant or Advisory Role - Lilly
T. C. Gauler
Consultant or Advisory Role - Lilly
Honoraria - Lilly
M. H. Schuler
Consultant or Advisory Role - Amgen; Celgene; Novartis
Honoraria - GlaxoSmithKline
Research Funding - Boehringer Ingelheim; Novartis; Roche
W. E. E. Eberhardt
Consultant or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; GlaxoSmithKline; ImClone Systems; Lilly; Merck; Merck Serono; Novartis; OSI Pharmaceuticals; Pfizer; Roche; Sanofi
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; GlaxoSmithKline; ImClone Systems; Lilly; Merck; Merck Serono; Novartis; OSI Pharmaceuticals; Pfizer; Roche; Sanofi
F. R. Hirsch
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Genentech; GlaxoSmithKline; ImClone Systems; Lilly; OSI Pharmaceuticals; Pfizer; Roche; Syndax; Ventana Medical Systems
Research Funding - AstraZeneca; Celgene; Merck; OSI Pharmaceuticals; Syndax; Ventana Medical Systems